Research
Every claim on this site traces to published clinical literature. These are the studies that define how we test, what we target, and what we expect optimisation to change.
Documented a secular, generation-independent decline in male serum testosterone that could not be explained by age, smoking or obesity alone.
The European Male Ageing Study showed clinical symptoms correlate far more strongly with free testosterone than with total testosterone.
Controlled weekly doses from 50 mg to 600 mg demonstrated a linear dose–response curve for lean mass, strength and fat loss across the physiological and mildly supraphysiological range.
Testosterone therapy increased tissue glucose uptake in response to insulin by 32–35% in men with type 2 diabetes.
In an 11-year registry, approximately 34% of hypogonadal men with type 2 diabetes achieved complete remission and discontinued antidiabetic medication.
A two-year randomised trial in 1,007 men: testosterone plus a lifestyle programme reduced the incidence of type 2 diabetes versus lifestyle alone.
Synthesises the metabolic, body-composition and quality-of-life evidence base for long-term testosterone therapy.
Landmark dermatological work showing local testosterone application thickened atrophic aged skin and improved dermal structure — evidence of tissue-level androgen dependence.
Bhasin's controlled dosing trials showed lean mass, strength and fat loss scale continuously with serum testosterone. Aiming at today's average of ~20 nmol/L means accepting a biology that a healthy man of the 1970s would have considered depleted.
The European Male Ageing Study demonstrated that symptom burden tracks bioavailable hormone. Reading total testosterone alone produces both false reassurance and missed diagnoses.
None of this is actionable until you know where you sit. Start with the two-minute symptom check, or go straight to bloodwork.